Current management of antiphospholipid syndrome-related thrombosis

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 12, 2009, Pages 1551-1558

  Puente, Dolores ^a   Pombo, Gonzalo ^a   Forastiero, Ricardo ^a  

^a FAVALORO UNIVERSITY   (Argentina)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Aspirin; Thrombosis; Warfarin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ARGATROBAN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; FONDAPARINUX; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACEBO; RITUXIMAB; THROMBIN INHIBITOR; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MATERNAL MORBIDITY; PLASMAPHERESIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; THROMBOSIS; WARFARIN;

EID: 73349127047     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.112     Document Type: Review

References (67)

1. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 113, 985-994 (2009).
2. Forastiero R, Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. Curr. Rheumatol. Rev. 1, 177-187 (2005).
3. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of b 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105, 1540-1545 (2005).
4. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42, 1309-1311 (1999).
5. Miyakis, S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295-306 (2006). •• Consensus addressing the newly existing evidence on clinical manifestations and laboratory features of the antiphospholipid syndrome (APS).
6. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. 66, 927-930 (2007).
7. Ruffati A, Del Ross T, Ciprian M et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann. Rheum. Dis. 68, 397-399 (2009).
8. Asherson RA, Cervera R, de Groot PG et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12, 530-534 (2003). •• Consensus reached in catastrophic APS.
9. Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin. Thromb. Hemost. 34, 329-334 (2008).
10. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with lupus eryhtematosus. Lupus 16, 810-816 (2007).
11. Galli M, Borrelli G, Jacobsen EM et al. Clinical significance of different antiphospholipid antibodies in the WAPS (Warfarin in the Anti-Phospholipid Syndrome) study. Blood 110, 1178-1183 (2007).
12. Forastiero R, Martinuzzo M, Pombo G et al. A prospective study of antibodies to b2 glycoprotein I and prothrombin, and risk of thrombosis. J. Thromb. Haemost. 3, 1231-1238 (2005). • First prospective study reporting IgG antibodies to b2 glycoprotein I and prothrombin are independent risk factors of thrombosis recurrence in patients with lupus anticoagulant and/or anticardiolipin antibodies.
13. Bizzaro N, Ghirardello A, Zampieri S et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J. Thromb. Haemost. 5, 1158-1164 (2007).
14. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost. 93, 1147-1152 (2005).
15. Ruffatti A, Tonello M, Del Ross T et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb. Haemost. 96, 337-341 (2006).
16. Pengo V, Tripodi A, Reber G et al. Official communication of the scientific and standardization committee on lupus anticoagulant/phospholipid- dependent antibodies: update of the guidelines for lupus anticoagulant detection. J. Thromb. Haemost. 7, (2009) (In Press).
17. Wong RCW, Favaloro EJ. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. Semin. Thromb. Hemost. 34, 361-372 (2008).
18. Alarcón-Segovia D, Boffa MC, Branco W et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12, 499-503 (2003).
19. de Groot PG, Derksen RH. Antiphospholipid antibodies: update on detection, pathophysiology, and treatment. Curr Opin Hematol 11, 165-169 (2004).
20. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebocontrolled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56, 2382-2391 (2007). • Prospective study indicating that asymptomatic antiphospholipid antibodypositive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis.
21. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12, 518-523 (2003).
22. Petri, M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol. 25, 191-193 (1996).
23. Haque, S, Bruce, IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2, 423-430 (2005).
24. Mok, CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand. J. Rheumatol. 35, 85-95 (2006).
25. Hereng T, Lambert M, Hachulla E et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 17, 11-15 (2008).
26. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61, 29-36 (2009).
27. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-583 (2006).
28. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Artritis Rheum. 46, 1019-1027 (2002).
29. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch. Intern. Med. 157, 2101-2108 (1997).
30. Kearon C, Kahn S, Agnelli G, Goldhaber S, Raskob G, Comerota A. Antithrombotic therapy for venous thromboembolic disease: the Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 133, 454S-545S (2008).
31. Albers G, Amarenco P, Easton J, Sacco R, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 133, 630S-669S (2008).
32. Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3, 848-853 (2005). •• Randomized trial showing that both moderate- and high-intensity anticoagulation are similar in preventing recurrent thrombosis in APS.
33. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian Registry. Am. J. Med. 100, 530-536 (1996).
34. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104, 332-338 (1998).
35. Kasthuri RS, Roubey RAS. Warfarin and the antiphospholipid syndrome Does one size fit all? Arthritis Rheum. 57, 1346-1347 (2005).
36. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332, 993-997 (1995).
37. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349, 1133-1138 (2003). •• Randomized double-blind trial demonstrating that moderate-intensity warfarin is appropriate for patients with APS.
38. Castellino G, Cuadrado MJ, Godfrey T, Khamashta MA, Hughes GR. Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulation treatment Ann. Rheum. Dis. 60, 527-530 (2001).
39. Ruiz Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch. Intern. Med. 162, 1164-1169 (2002).
40. Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractioned heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349, 1695-1702 (2003).
41. Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat. Clin. Pract. Rheumatol. 5, 160-170 (2009).
42. Veneri D, Ambrosetti A, Franchini M, Mosna F, Poli G, Pizzolo G. Remission of severe antiphospholipid syndrome associated with non Hodgkin B cell lymphoma after combined treatment with rituximab and chemotherapy. Haematologica 90, 16-17 (2005).
43. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol. 33, 355-357 (2006).
44. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. CD000213 (2003).
45. LaMonte MP, Nash ML, Wang DZ et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 35, 1677-1682 (2004).
46. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med. 32, 976-980 (2004).
47. Levine SR, Brey RL, Tilley BC et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291, 576-584 (2004). • Concludes that antiphospholipid antibodies do not influence the occurrence of a recurrent event and that warfarin and aspirin therapy are equivalent in stroke prevention.
48. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: the Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 133, 844S-886S (2008).
49. Espinosa G, Bucciarelli S, Cervera R, Gómez-Puerta JA, Font J. Laboratory features on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun. Rev. 6, 68-71 (2006).
50. Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome in 2004 - a review. Autoimmun. Rev. 4, 48-54 (2005).
51. Cervera R, Bucciarelli S, Plasin M et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the CAPS registry. J. Autoimmun. 32, 240-245 (2009).
52. Bucciarelli S, Espinosa G, Cervera R et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 54, 2568-2576 (2006).
53. Marson P, Bagatella P, Bortolati M et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J. Intern. Med. 264, 201-203 (2008).
54. Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J. Rheumatol. 34, 346-352 (2007).
55. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 210, 727-733 (2005).
56. Pierangeli SS, Vega-Ostertag M, Gonzalez EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert. Rev. Mol. Med. 9, 1-15 (2007).
57. Vega-Ostertag M, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr. Rheumatol. Rep. 9, 190-197 (2007).
58. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109, 422-430 (2007). • Important review examining the experimental evidence underlying the most important pathogenic mechanisms of APS.
59. Edwards MH, Pierangeli SS, Liu X, Baxter JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96, 4380-4384 (1997).
60. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-b2-glycoprotein I complexes to phospholipid bilayers. Blood 112, 1687-1695 (2008).
61. Erkan D, Yasici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41, 924-929 (2002).
62. Ho TK, Ahn W, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 44, 1303-1307 (2005).
63. Ferrara DE, Liu X, Espinola RG et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal mode. Arthritis Rheum. 48, 3272-3279 (2003).
64. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z et al. Role of p38 mitogenactivated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J. Thromb. Haemost. 5, 1828-1834 (2007).
65. Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E et al. In vivo effects of an inhibitor of nuclear factor-k B on thrombogenic properties of antiphospholipid antibodies. Ann. NY Acad. Sci 1108, 540-553 (2007).
66. Pierangeli SS, Blank M, Liu X et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J. Autoimmun. 22, 217-225 (2004).
67. Vega-Ostertag ME, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth domain of b-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in vivo. Lupus 15, 358-365 (2006).